News | June 11, 2026
Glenmark launches Winlevi across key European markets
First-in-class topical androgen receptor inhibitor marks Glenmark’s first New Chemical Entity (NCE) launch in Europe
First-in-class topical androgen receptor inhibitor marks Glenmark’s first New Chemical Entity (NCE) launch in Europe
New-generation platform enhances anatomical visualization, streamlines surgical workflows, and expands access to advanced navigation technology for ENT surgeons across Europe
Teva said the launch strengthens its biosimilars strategy and expands access to biologic medicines across Europe
The approval is expected to support the company’s presence in regulated international markets and further strengthen its position as a reliable pharma manufacturing partner
The aflibercept biosimilar, referencing Eylea, becomes the company’s fifth directly commercialized biosimilar in Europe, expanding access to ophthalmology treatments
Increasing syphilis cases, stronger STI surveillance initiatives, and growing emphasis on early diagnosis are expected to support sustained demand
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
The approval was granted by Agenzia Italiana del Farmaco
Next-generation berberine formulation developed with BioSOLVE Technology targets metabolic health, blood sugar balance, and weight management
This is an exciting and meaningful milestone for GRIN Therapeutics
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
